You're signed outSign in or to get full access.
Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. is a healthcare-focused investment firm headquartered in Palo Alto, CA, USA. It manages both venture and public investment funds targeting novel therapeutic companies. Founded in 2005, the firm specializes in company creation, early stage venture investments, and public biotech investments. The firm manages several billion dollars in assets and employs a team of professionals with deep domain expertise in life sciences, serving entrepreneurs, private and public biotech companies, and institutional investors.
Investment Strategy
Frazier Life Sciences pursues investments in therapeutics companies across all stages, with its Venture Funds focusing on the creation and early-stage private companies (over 30 companies created since 2005) and Series A/B opportunities. The Public Funds deploy capital to small- and mid-cap public biotech firms through PIPEs, CMPOs, IPOs, and open market support. The firm's approach emphasizes partnering closely with entrepreneurs and management teams to build valuable companies and advance novel therapeutics for patients. They have raised multi-billion dollar funds and invest globally in therapeutics innovation.
Latest 13F Filing Activity
Frazier Life Sciences Management, L.P. filed their most recent 13F report on Jun 30, 2025 disclosing 48 equity positions with a total 13F market value of $3B. The fund increased holdings in Verona Pharma PLC, Phathom Pharmaceuticals Inc., Mirum Pharmaceuticals Inc. among other positions. Frazier Life Sciences Management, L.P. reduced exposure to Rhythm Pharmaceuticals Inc., Soleno Therapeutics Inc., Krystal Biotech Inc. among others.
Top Holdings
Equity Positions (48)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
M MIRM | MIRUM PHARMACEUTICALS INC | 13.83% | $345.8M | 6,795,121 | $26.20 | $50.89 | +$39.7M |
V VRNA | VERONA PHARMA PLC | 12.80% | $320.1M | 3,383,950 | $15.98 | $94.58 | +$100.5M |
N NAMS | NEWAMSTERDAM PHARMA COMPANY | 12.03% | $300.8M | 16,607,074 | $14.20 | $18.11 | -$29.1M |
B BBIO | BRIDGEBIO PHARMA INC | 6.56% | $164.1M | 3,800,457 | $21.95 | $43.18 | +$32.7M |
A ARQT | ARCUTIS BIOTHERAPEUTICS INC | 5.54% | $138.4M | 9,874,511 | $18.53 | $14.02 | +$1.0M |
Industry Allocation
Investment Team (11)
| Name | Role | Location | |
|---|---|---|---|
 | Partner | New York, NY , United States | |
 | General Partner | San Diego, CA , United States | |
 | Senior Associate | Menlo Park, CA , United States | |
 | Managing Partner | Menlo Park, CA , United States | |
A Albert Cha | Managing Partner | Los Altos, CA , United States | |
A Angel Martin | Senior Associate | CA , United States | |
 | Partner | San Diego, CA , United States | |
 | Senior Associate | Palo Alto, CA , United States | |
 | Principal | Boston, MA , United States | |
 | Principal | Palo Alto, CA , United States |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more